Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Greenwich Lifesciences, Inc. (GLSI)
:GLSI
GLSI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$10.52 - $21.44
Previous Close$13.65
Volume34.11K
Average Volume (3M)33.41K
Market Cap
$164.70M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.42
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.81
Shares Outstanding13,144,653
10 Day Avg. Volume22,091
30 Day Avg. Volume33,408
Standard Deviation0.84
R-Squared0.03
Alpha0.08
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-16.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$38.00Price Target Upside201.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Bulls Say, Bears Say
Bulls Say
Safety ProfileNo serious adverse events related to GLSI-100 have been reported to date.
Trial ExpansionExpansion of clinical sites across Europe and U.S. clears the way to activate approximately 110-115 sites in Europe.
Trial PerformanceIn the Phase 2 trial, GLSI-100 treatment resulted in no recurrences or a 100% reduction in recurrence rate in the sub-population that the FLAMINGO-01 trial design has been based upon.
Bears Say
Financial NeedsThe company may need to raise additional capital within the next 12 months.
Trial ComplexityThe non-HLA-A*02 arm was recently expanded from 100 to 250 patients based on recommendation of the steering committee and approvals by the FDA and EMA.
Trial Design ChallengesAn interim analysis for superiority or futility would be conducted when at least 14 events have occurred, supporting the ongoing evaluation of the trial's effectiveness.
---
Ownership Overview
55.06% Insiders
3.22% Mutual Funds
0.04% Other Institutional Investors
38.03% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
GLSI FAQ
What was Greenwich Lifesciences, Inc.’s price range in the past 12 months?
Greenwich Lifesciences, Inc. lowest stock price was $10.52 and its highest was $21.44 in the past 12 months.
What is Greenwich Lifesciences, Inc.’s market cap?
Greenwich Lifesciences, Inc.’s market cap is $164.70M.
When is Greenwich Lifesciences, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Greenwich Lifesciences, Inc.’s earnings last quarter?
Currently, no data Available
Is Greenwich Lifesciences, Inc. overvalued?
According to Wall Street analysts Greenwich Lifesciences, Inc.’s price is currently Undervalued.
Does Greenwich Lifesciences, Inc. pay dividends?
Greenwich Lifesciences, Inc. does not currently pay dividends.
What is Greenwich Lifesciences, Inc.’s EPS estimate?
Greenwich Lifesciences, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Greenwich Lifesciences, Inc. have?
Greenwich Lifesciences, Inc. has 13,144,653 shares outstanding.
What happened to Greenwich Lifesciences, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Greenwich Lifesciences, Inc.?
Currently, no hedge funds are holding shares in GLSI
---
Greenwich LifeSciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$38.00 (201.83% Upside)
$38.00 (201.83% Upside)
Blogger Sentiment
Bearish
GLSI Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $214.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
12.01%
12-Months-Change
Fundamentals
Return on Equity
-151.72%
Trailing 12-Months
Asset Growth
-36.34%
Trailing 12-Months
Company Description
Greenwich Lifesciences, Inc.
Greenwich LifeSciences Inc is a clinical stage bio-pharmaceutical company focused on the development of an immunotherapy to prevent breast cancer recurrences in patients.
---
GLSI Stock 12 Month Forecast
Average Price Target
$38.00
▲(201.83% Upside)
Technical Analysis
Best Analysts Covering GLSI
1 Year
1 Year Success Rate
2/7 ratings generated profit
1 Year Average Return
-6.07%
reiterated a buy rating 12 days ago
Copying Yi Chen's trades and holding each position for 1 Year would result in 28.57% of your transactions generating a profit, with an average return of -6.07% per trade.
---